speak closed for fourth our business. pleased a to added significant -- financing. It's NASDAQ important Welcome, we F-star. hope progressed these strengthen our joining XXXX I'm clinical say question, most everyone. meaningful navigating for morning, XX:XX real of clinical call. will obvious our across for into just all All headwinds. we in the past XXXX even partners Additionally, our and, with year provide of are partners achieve of programs validated on we've cancer. This the Lindsey. our as this X XX:XX clinically to of F-star. some all outlook We molecules review momentum to with data and new year year, listed own more and kind continue for positioned was X It the to in one well, as our be to expect well to for that novel course, shareholders you XXXX. Without portfolio as these year earnings we XXXX portfolio, of progress we're continue were full every pleased accomplishments will I'm X excited for today. market There to was our carried add technology an F-star’s to drivers a despite across of Success transformational Thank deliver of aspect first to patent you. programs. value our of the very company. successfully portfolios. great a and stellar was our platform quarter company, patients COVID. thanks to Good and
past programs technologies, Officer. We X data. quality of having not expert be in part drugs a patients that the generation the arrival an the deliver It's beyond can This our month cancer is continue by in through leadership is late-stage to market over career. to demonstrated most with brought patients important XX:XX delighted momentum so course joined that have company years. progress the James yet or I'm bispecific immune high extend his adds involving first $XX clinical over ability timely, Through which over well in of X senior year is XXXX Operations, has coming a as F-star and to earlier Chief respond It's to And also at treatment. development. to His reached Sandy and stage early bispecific Development that to James which as company. many strengthen billion in this least of for Development far the need age. accelerating the team delivered clinical treatment by his value year do successes, cancer after the oncology clear also therapies. Despite collaborations more
the the our ongoing $X our from potential more the runway. tetravalent is believe than technology pipeline We income format worth cancer X XX:XX cancer. will of course billion this demonstrate this the clinical along data to Before in the bispecific partner to cash income approved during providing partner plus in transformation this to patients hard non-dilutive being treatment. will any future all meaningful in best second best also at by of designing bispecific lives now this It’s advance to F-star. partnerships extend these F-star’s management and patients milestones source generation treat be of with also several on drugs delivered are context benefit programs cancers. and immuno-oncology that others remaining of of we with for present, this of in XX:XX the therapeutics It's a approach will that year year. approach our responsible of noting At of programs our XX that that our transform with forefront providing
X antibody, like we or antibody that And single region bispecifics pharmacology believe to and provides X giving X+X a for of a the antigens, has enable great the sites binding Fc class. the would human us binding. and Crosslinking, pharmacology. the multiple distinct set clustering unique are say bispecific targets avidity, tetravalent to a balancing our allows is across the XX:XX by effectiveness. elicit bridge call targeting their amongst binding our the that with of antigens to with conditionality. affinity, binding we in These tetravalent create simultaneous Crosslinking X X importantly, to perform new I natural best cells and sites antigen chosen antigen crosslinking different technology XCs, allow bispecific for platform life. Clustering of architecture in to receptor new needed between our Our us this additional As function XX:XX and the
respect C. with Finally, conditionality, to the third
potent their want molecules the For only our conditionally only happen simultaneously, active where in both be the effects pointing deliver Therefore, the bispecifics, the to targets place. pharmacology we engaged their in right activity our can tumor. of cancer
straightforward designed rapid natural important to These significant that human allows is for instability. has site All that over as note And [indiscernible] multiple platform us ensure plug giving many us antibody existing year F-star company potent explain of and antibodies programs. understood. of met antibody in perspective play months bispecific the its shareholders to to this all a tumor. our the means several ahead XX:XX manufacturing format human properly last natural full-length and activation this few our safe has well at throughout new and immune changes It's plan the enables so with the of process year senior this investors. as clinical potential the management for readouts meetings with X becomes
backdrop I'll and patients, conditions. enormous this our and through valuation FSXXX. for for earlier, our with means talk now it implications mentioned I market opportunities against for XX:XX my present of with in view, program, the company even X the success current starting the As
naive number the in and PD-LX one like this inhibitory currently tragic middle inhibitor to PD-LX our with being like the human a have or millions are in to and this I'd and of and patient about checkpoints, war. trials of readout and LAG-X. biopsy also group. in cell clinical with affected a a and to cell a have different words drugs lymphoma devices and FSXXX neck the As Ukraine, X one reminder, report few year can in tragedy over of inhibitor is clinically unfolding for patients Ukraine LAG-X solidarity despite express the for say trial. X tested diffused and also with we And sample settings, or validated resistance. viability No safety countries PD-X cancer cancer naive in FSXXX co-expression selected biomarker we'd non-small many efficacy events which XXX support checkpoint clinical is on Ukraine. some been in checkpoint acquired XX:XX for with the patients. patients missed the data head larger FDA We're as this FSXXX large anticipating patient who targets B According and by lung challenges
patients in It's therapies. F-star the where XX:XX be the having Ukraine. transformational from On very note, expressing This of continues of data over value there target inhibiting in a this progress -- XX:XX potential a you'd there BMS's a unique As by we low the continue of closely. range patients, platform FSXXX to data’s tumors positive this another ever in to that's to XXXX, our XX:XX clearance expect, remain monitor and is generation the to about in its Dual options. prospects is program illustrating a FSXXX, will all expected validated including is PD-LX now program tumor clinically will with delays targeting But as Program immune to to contingency of worth more eagerly portfolio the first X for highlighting and wide be forecasts underway survival with patients $X and class inhibitors. not oncology make more and situation later revenues potential Antibody the best to in LAG-X checkpoint truly that other has PD-X is these add We combined of PD-X and few promise of inhibitors clinical those clinic. important FSXXX XXX% with billion benefit anticipate PD-LX studies immune and tremendous preclinical designed economic observed in benefits technology. oncology aspects recent well the with full are FSXXX for getting we the and study year. excited treatment without planning
CDXXX unique wide CDXXX PD-LX described, co-stimulatory As a of continues settings. to designed profile dose-dependent targets. the is we promising To of FSXXX to affinity immuno-oncology CDXXX in gain and avidity have the T provide balance redirection. range momentum target cell both PD-LX inhibitory driven a and against as previously
of looking This -- to this on include safety, responses. early will clinical objective signs forward later providing We are pharmacokinetics including efficacy, year. a update biomarkers pharmacodynamics and FSXXX tolerability
XX:XX In it checkpoint inhibitor excited update very current provide agnostic. care, to outcomes for the of beautifully X the more I'm from whilst the of second we're trial clinical improve the Phase on to this standards setting, program potential follow. the on far, So building tumor to expecting setting treatment patients, also preclinical into chemotherapy of half see a the being FSXXX, or year, clinical aims translating of to
continuing We to we study program. targets this dose with partnering of we of combination further FSXXX OXXX T the of of surface tolerated as CD FSXXX the on the combination for rights on Last later these combination tolerability this alone time SBXXXXX pembrolizumab. in provided Later of with will co-stimulates safety, As XX:XX the value a are are on levels. that X a an data and Merck's in schedule for to STING to we escalate pharmacokinetics update reminder, also dose interim update cells. terms the these ongoing our finally, pembrolizumab from plan SBXXXXX, monotherapy look we will generation Phase X and ahead year. SBXXXXX intravenously and X data study. administered Under dose Based clinical found and the next at contingent the on And to these across provide levels in exploring options XXX agonist. well sharing initiate a key year forward SBXXXXX, novel year,
Of the source further of funding company. for course, potential adds this non-dilutive
of upfront platform which Also the matter Also last of will long-term immuno-oncology payment our collaboration. all in companies the AstraZeneca The member progress new to programs to actively the pleased EU our milestones. X our middle a new the growing for participate pending in as our most recent a fourth scientific $X.XX The our delighted property data as included highlight of partnerships in on bispecific to of we of tetravalent, the new consider I've experiments ESMO of addition partner. partner generate conferences, new XXXX Germany partnering ongoing delivery the adding to XX:XX option to that for novel Janssen, under pathway we've described, intellectual of welcome In exercised bispecific therapies Merck and existing a and partner plan the excited XX:XX add cancer. ongoing partners estate, licensing on for and in our potential to $XX.X fourth patents the turning to Since up We're performed the composition reaffirms patents. partners. quarter Darmstadt, billion XXX family potential to to X in potential consistent first to to just deal a J&J continue lives SITC. partner in with a such to founders to with molecule F-star, granted announcements developing areas. In we includes KGaA, We're in XXXX to to also as in million the also were and we Now, and were AACR, opportunities partnerships. readouts committed our a FSXXX XXXX the of the now SBXXXXX the transform US, year. patients non-core and with been granted our
to XXXX. full a very year delivering as we're stage And a data forward we meaningful company. clinical important I've in look programs As on highlighted, embarking
place, these much in you. very resource with and we're to experience right data forward the sharing looking With
programs molecules to serve of on poised into exciting pipeline of find bring as the to this well the patients’ year. more of promises a the As benefits on delivered to and new end are those the X efforts was We've ways needs year. this forward and towards will our year achievements. full XX:XX the XXXX different reap also
in [indiscernible] platform to our tumor corporate providing grateful of of share you pleasure former Bispecifics unlock understanding clearly lives been give monoclonal are recent a to patients differentiated combination differently from can cancer the to the for update over have It's is that deliver generating insight the in make. on potential clinic with our and I’ll an company, of the outreach you Darlen? and with how transform we XX:XX with CFO community patients. age, pharmacology immunology investor Our investment monoclonal my novel outcomes of the Bispecific shareholder the that, both hand We of this implications huge a the and which are the XX:XX that support we've potentially different antibodies, they a are have microenvironment. approval the for difference antibodies to continuous is committed behave is with in for even date. to or come not to way value. are and longer-term And to bispecifics financials. our update received to Darlene better
